A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP ...

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has announced funding for a new project ...

AstraZeneca and Merck & Co's Lynparza has been the undisputed market leader in the PARP inhibitor category for some years, but would-be competitors continue to chip away at its market share.

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median ...

AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term results ...

亲爱的读者们，今日上午10点钟，与我们一起深入探索肿瘤药物研发的新领域——聚腺苷二磷酸核糖聚合酶（PARP）抑制剂。这种药物以其独特的协同致死机制引起了广泛关注，将为癌症治疗带来新的突破。

A recent report shows that several 'poly-ADP-ribose-polymerases' may function exclusively as a family of endogenous mono-ADP-ribosyltransferases, providing a new, molecularly less complex and ...

这一进展不仅为患者带来了新的治疗选择，也进一步巩固了氟唑帕利作为国内首款获批治疗乳腺癌的PARP抑制剂的地位。乳腺癌作为全球女性最常见的恶性肿瘤之一，其发病率和死亡率在全球范围内均呈现上升趋势。HER2阴性乳腺癌尤其难以治疗，因为它发展迅速，容易转移 ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

A new study demonstrates how universal genetic testing for breast cancer can ensure no patient is missed for advanced ...